Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Previous, small studies have suggested that ondansetron has beneficial effects in diarrhea-predominant irritable bowel syndrome (IBS-D). This randomized, double-blind study evaluated the efficacy and safety of daily 12 mg RHB-102, an investigational bimodal release ondansetron tablet, in IBS-D. METHODS: Men and women with IBS-D by the Rome III criteria, Bristol Stool Scale ≥6 on 2 or more days weekly, and average daily worst pain intensity ≥3/10 were randomized 60:40 to RHB-102 or placebo once daily for 8 weeks. The primary end point was overall stool consistency response for at least 4 of 8 weeks. Secondary end points included overall worst abdominal pain and overall composite response, defined as response on both abdominal pain and stool consistency end points. RESULTS: Overall stool consistency response rates were 56.0% and 35.3% (RHB-102 vs placebo, P = 0.036) and similar among male and female patients. Overall pain response (50.7% vs 39.2%) and composite response rates (40.0% vs 25.5%) favored RHB-102, although these differences were not statistically significant. Stool consistency response rates were enhanced in patients with baseline C-reactive protein above the median (2.09 mg/L), 59.5%, vs 23.1% ( P = 0.009). Overall rates of adverse events were similar, with a higher rate of constipation in RHB-102 patients (13.3% vs 3.9%) that resolved rapidly on withholding treatment. DISCUSSION: RHB-102 was effective and safe in the treatment of men and women with IBS-D. Baseline C-reactive protein seemed to be predictive of response.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A subsequent RCT of 12 mg once a day of bimodal release ondansetron also demonstrated superiority over placebo for improvement in stool consistency, but not abdominal pain.178”
From British Society of Gastroenterology guidelines on the management of irritable bowel syndrome (2021) · cites this paper as [178]
Citations
Cites
Lacy, B. E., Mearin, F., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.031 · Cited by 2,866
Serotonin signalling in the gut: functions, dysfunctions and therapeutic targets
Mawe, G. M., & Hoffman, J. M. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.105 · Cited by 1,165
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036 · cited 1×
“The magnitude of effects was comparable with thosewith other approved products for IBS-D, alosetron (17,18), rifaximin (19), and eluxadoline (20) across all study end points.”
ResultIrritable bowel syndrome in the United States: prevalence, symptom patterns and impact
Hungin, A. P. S., Chang, L., Locke, G. R., Dennis, E. H., & Barghout, V. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02463.x · Cited by 494 · cited 1×
“Four IBS subtypes have been described; diarrhea-predominant (IBS-D)accounts for 30%–45%of allUS adult patientswith IBS (7).”
BackgroundEluxadoline for Irritable Bowel Syndrome with Diarrhea
Lembo, A. J., Lacy, B. E., Zuckerman, M. J., Schey, R., Dove, L. S., Andrae, D. A., Davenport, J. M., McIntyre, G., Lopez, R., Turner, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505180 · Cited by 334 · cited 1×
“The magnitude of effects was comparable with thosewith other approved products for IBS-D, alosetron (17,18), rifaximin (19), and eluxadoline (20) across all study end points.”
ResultCamilleri, M., Chey, W. Y., Mayer, E. A., Northcutt, A. R., Heath, A., Dukes, G. E., McSorley, D., & Mangel, A. M. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.14.1733 · Cited by 302
A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea
Garsed, K., Chernova, J., Hastings, M., Lam, C., Marciani, L., Singh, G., Henry, A., Hall, I., Whorwell, P., & Spiller, R. (2014) · Gut · doi:10.1136/gutjnl-2013-305989 · Cited by 246
IBS and IBD — separate entities or on a spectrum?
Spiller, R., & Major, G. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.141 · Cited by 163
The putative role of the intestinal microbiota in the irritable bowel syndrome
Collins, S. M., Denou, E., Verdu, E. F., & Berčík, P. (2009) · Digestive and Liver Disease · doi:10.1016/j.dld.2009.07.023 · Cited by 133
Epithelial expression and function of trypsin-3 in irritable bowel syndrome
Rolland-Fourcade, C., Denadai-Souza, A., Cirillo, C., Lopez, C., Jaramillo, J. O., Desormeaux, C., Cenac, N., Motta, J.-P., Larauche, M., Taché, Y., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-312094 · Cited by 126
Research works printed but not linked: 1
- Sayegh, 2015, Comparative bioavailability study of RHB-102 (24 mg ER tablets QD) versus ondansetron 8 mg trablets BID and a single dose of ondansetron 24 mg in healthy volunteers, Clin Pharm Ther, 97, S47
Cited by
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome
Vasant, D. H., Paine, P. A., Black, C. J., Houghton, L. A., Everitt, H. A., Corsetti, M., Agrawal, A., Aziz, I., Farmer, A. D., Eugenicos, M. P., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324598 · Cited by 592
Savarino, E., Zingone, F., Barberio, B., Marasco, G., Akyuz, F., Akpinar, H., Barboi, O., Bodini, G., Bor, S., Chiarioni, G., et al. (2022) · United European Gastroenterology Journal · doi:10.1002/ueg2.12259 · Cited by 146
Italian guidelines for the management of irritable bowel syndrome
Barbara, G., Cremon, C., Bellini, M., Corsetti, M., Nardo, G. D., Falangone, F., Fuccio, L., Galeazzi, F., Iovino, P., Sarnelli, G., et al. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2022.11.015 · Cited by 88
Pharmacological Therapies and Their Clinical Targets in Irritable Bowel Syndrome With Diarrhea
Colomier, E., Algera, J. P., & Melchior, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.629026 · Cited by 60
Nee, J. W., & Lembo, A. J. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16625 · Cited by 51
Metadata
- Authors
- Plasse, T. F., Barton, G., Davidson, E., Abramson, D., Kalfus, I., Fathi, R., Raday, G., & Harris, M. S.
- Affiliations
- RedHill Biopharma, Tel Aviv, Israel;
- Arkansas Gastroenterology, PA, North Little Rock Arkansas, USA;
- New Phase Research & Development, Knoxville, Tennessee, USA;
- Middleburg Consultants, Takoma Park, Maryland, USA.
- Corresponding author
- Plasse, Terry F.
- Venue
- American Journal of Gastroenterology
- Published
- 2020-06-24
- Volume
- 115
- Issue
- 9
- Pages
- 1466-1473
- ISSN
- 0002-9270 (ISSN-L)
- 1572-0241
- OpenAlex
- W3041749458
- Cited by
- 40
- References
- 17
- Citations by year
- 2025: 8 · 2024: 7 · 2023: 4 · 2022: 7 · 2021: 9 · 2020: 4
- FWCI
- 5.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The American Journal of Gastroenterology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
- Keywords
- ondansetron, diarrhea-predominant irritable bowel syndrome, stool consistency, abdominal pain, C-reactive protein, treatment response prediction
- MeSH terms
- Adolescent, Adult, Aged, Defecation, Diarrhea, Double-Blind Method, Female, Gastrointestinal Agents, Humans, Male, Middle Aged, Abdominal Pain, Treatment Outcome, Ondansetron, Irritable Bowel Syndrome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial. https://app.cochat.ai/papers/10.14309/ajg.0000000000000727
- The paper
- Plasse, T. F., Barton, G., Davidson, E., Abramson, D., Kalfus, I., Fathi, R., Raday, G., & Harris, M. S. (2020). Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial. American Journal of Gastroenterology. https://doi.org/10.14309/ajg.0000000000000727
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.